The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...

Secretary Robert F. Kennedy Jr. said he is considering a “regulatory framework” for Medicare and Medicaid to cover GLP-1 ...

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability issue of obesity medications such as Wegovy and Zepbound.

LifeMD's growth accelerates with expanded insurance, new health products, and a 43% revenue boost. Click here to read our ...

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...

President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a ...